UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nitric oxide and cancer: the emerging role of S-nitrosylation

Current molecular medicine, 2012-01, Vol.12 (1), p.50-67

2012

Volltextzugriff (PDF)

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials

European journal of cancer (1990), 2019-08, Vol.117, p.91-98

2019

Volltextzugriff (PDF)

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

Annals of oncology, 2012-12, Vol.23 (12), p.3069-3074

2012

Volltextzugriff (PDF)

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial

Annals of oncology, 2015-12, Vol.26 (12), p.2429-2436

2015

Volltextzugriff (PDF)

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

Clinical & translational oncology, 2017-12, Vol.19 (12), p.1454-1461

2017

Volltextzugriff (PDF)

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial

ESMO open, 2024-09, Vol.9 (9), p.103699, Article 103699

2024

Volltextzugriff (PDF)

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

British journal of cancer, 2014-03, Vol.110 (5), p.1139-1147

2014

Volltextzugriff (PDF)

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

European journal of cancer (1990), 2022-01, Vol.161, p.26-37

2022

Volltextzugriff (PDF)

Fulvestrant in advanced male breast cancer

Annals of oncology, 2009-11, Vol.20 (11), p.1896-1897

2009

Volltextzugriff (PDF)

Epirubicin–cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study

Annals of oncology, 2004-01, Vol.15 (1), p.79-87

2004

Volltextzugriff (PDF)

Electronic health records and patient registries in medical oncology departments in Spain

Clinical & translational oncology, 2021-10, Vol.23 (10), p.2099-2108

2021

Volltextzugriff (PDF)

Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study

ESMO open, 2024-10, Vol.9 (10), p.103733, Article 103733

2024

Volltextzugriff (PDF)

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

Clinical & translational oncology, 2020-03, Vol.22 (3), p.420-428

2020

Volltextzugriff (PDF)

SEOM clinical guidelines for the management of metastatic breast cancer 2013

Clinical & translational oncology, 2013-12, Vol.15 (12), p.1004-1010

2013

Volltextzugriff (PDF)

GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment

Current drug metabolism, 2007-06, Vol.8 (5), p.481-486

2007

Volltextzugriff (PDF)

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

Clinical & translational oncology, 2013-10, Vol.15 (10), p.810-817

2013

Volltextzugriff (PDF)

1882 CASCADE study: Epidemiological analysis of current natural history and treatment patterns of metastatic breast cancer in spain

European journal of cancer (1990), 2015-09, Vol.51, p.S293-S294

2015

Volltextzugriff (PDF)

Application of near-infrared microscopy (NIRM) for the detection of meat and bone meals in animal feeds: A tool for food and feed safety

Food chemistry, 2007, Vol.105 (3), p.1164-1170

2007

Volltextzugriff (PDF)

Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies

Annals of oncology, 2018-10, Vol.29, p.viii61-viii61

2018

Volltextzugriff (PDF)

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

Clinical & translational oncology, 2015-02, Vol.17 (2), p.160-166

2015

Volltextzugriff (PDF)

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

Clinical & translational oncology, 2017-05, Vol.19 (5), p.616-624

2017

Volltextzugriff (PDF)

Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial

Breast cancer research and treatment, 2009-07, Vol.116 (2), p.351-358

2009

Volltextzugriff (PDF)

Endothelial nitric oxide synthase in colorectal cancer: A potential new therapeutic target in stem cell-like poor-prognosis subtype

European journal of cancer (1990), 2016-12, Vol.69, p.S46-S46

2016

Volltextzugriff (PDF)

1 – 25 von 290

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(242)
Mit Volltextzugriff
(258)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(72)
Life Sciences & Biomedicine
(66)
Humans
(41)
Female
(32)
Oncology
(32)
Aged
(26)
Middle Aged
(26)
Adult
(24)
Biological And Medical Sciences
(24)
Breast Neoplasms - Drug Therapy
(19)
Fundamental And Applied Biological Sciences. Psychology
(17)
Breast Neoplasms - Pathology
(15)
Plant Sciences
(14)
Breast Cancer
(13)
Plant Physiology And Development
(13)
Prognosis
(13)
Helianthus Annuus
(12)
Medicine
(12)
Medicine & Public Health
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Nitric oxide and cancer: the emerging role of S-nitrosylation

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

Fulvestrant in advanced male breast cancer

Epirubicin–cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study

Electronic health records and patient registries in medical oncology departments in Spain

Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

SEOM clinical guidelines for the management of metastatic breast cancer 2013

GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

1882 CASCADE study: Epidemiological analysis of current natural history and treatment patterns of metastatic breast cancer in spain

Application of near-infrared microscopy (NIRM) for the detection of meat and bone meals in animal feeds: A tool for food and feed safety

Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial

Endothelial nitric oxide synthase in colorectal cancer: A potential new therapeutic target in stem cell-like poor-prognosis subtype

Suchergebnisse filtern